These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. Bucher HC; Bichsel M; Taffé P; Furrer H; Telenti A; Hirschel B; Weber R; Bernasconi E; Vernazza P; Minder C; Battegay M; HIV Med; 2002 Oct; 3(4):247-53. PubMed ID: 12444942 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K; HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686 [TBL] [Abstract][Full Text] [Related]
7. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J; Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443 [TBL] [Abstract][Full Text] [Related]
8. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B J Acquir Immune Defic Syndr; 1999 Oct; 22(2):132-8. PubMed ID: 10843526 [TBL] [Abstract][Full Text] [Related]
9. Darunavir: a review of its use in the management of HIV infection in adults. McKeage K; Perry CM; Keam SJ Drugs; 2009; 69(4):477-503. PubMed ID: 19323590 [TBL] [Abstract][Full Text] [Related]
10. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B; J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902 [TBL] [Abstract][Full Text] [Related]
11. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
12. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850 [TBL] [Abstract][Full Text] [Related]
14. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. Lucas GM; Chaisson RE; Moore RD AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943 [TBL] [Abstract][Full Text] [Related]
15. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml. Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091 [TBL] [Abstract][Full Text] [Related]
17. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Plosker GL; Scott LJ Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort. Brunet C; Reliquet V; Jovelin T; Venisse N; Winer N; Bui E; Le Moal G; Perfezou P; De Saint Martin L; Raffi F Med Mal Infect; 2012 Sep; 42(9):421-8. PubMed ID: 22938775 [TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
20. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW; JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]